Vyleesi Compounding Legal Status: What Patients and Prescribers Need to Know

What the FDA Approval Actually Covers

Vyleesi earned FDA approval under NDA 210557 on June 21, 2019, making bremelanotide the second FDA-approved pharmacologic treatment for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. The first was flibanserin (Addyi), approved in 2015. Both operate through entirely different mechanisms, and neither approval covers postmenopausal women, secondary HSDD, or situational low desire.

The approval is narrow by design. The FDA label specifies a single dose: 1.75 mg delivered subcutaneously via a prefilled, single-use autoinjector, taken approximately 45 minutes before anticipated sexual activity. Patients should not use more than one dose in any 24-hour period, and the label recommends no more than one dose per day as needed. Chronic daily dosing is not part of the approved regimen, in part because of the hyperpigmentation risk discussed below.

What NDA 210557 Does and Does Not Authorize

The NDA authorizes Palatin Technologies (and its commercial partners) to market the 1.75 mg autoinjector under the brand name Vyleesi. It does not authorize:

• Compounded formulations at any dose
• Intravenous or intramuscular routes
• Use in postmenopausal women
• Use in men
• Combination with phosphodiesterase-5 inhibitors under a co-promotion arrangement

The prescribing information is publicly available through FDA Drugs@FDA for NDA 210557. Every compounding pharmacy, telehealth platform, and prescriber should cross-reference that document before dispensing any form of bremelanotide. [1]

The Specific Population Language

The label language matters legally. The FDA-approved indication reads: "treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance."

That "NOT due to" clause excludes a wide swath of real-world patients, meaning off-label use is common but unprotected by the NDA.

Bremelanotide Compounding Legal Status Under Federal Pharmacy Law

Compounding bremelanotide is not straightforwardly legal while an FDA-approved equivalent is commercially available. Two federal statutes govern this:

Section 503A: Traditional Compounding Pharmacies

Under Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act), a licensed pharmacist may compound a drug for an identified individual patient based on a valid prescription. However, 503A pharmacies may not compound "essentially a copy" of a commercially available drug product. Because Vyleesi (bremelanotide 1.75 mg) is commercially available, a 503A pharmacy that compounds bremelanotide at the same dose and route is likely compounding an essentially-a-copy product, which is prohibited.

A pharmacist could argue clinical differentiation (a different dose, a different concentration for a patient who cannot tolerate the 1.75 mg injection) but that argument requires documented clinical rationale and prescriber attestation. Routine dispensing of compounded bremelanotide without such documentation exposes both the pharmacy and the prescriber to FDA enforcement action.

Section 503B: Outsourcing Facilities

Under Section 503B, FDA-registered outsourcing facilities may produce larger-scale compounded preparations, but only from bulk drug substances on FDA's 503B bulks list. As of the date of this article's last review (July 2025), bremelanotide does not appear on the FDA's list of bulk drug substances for use by outsourcing facilities. That absence means a 503B outsourcing facility cannot lawfully use bulk bremelanotide to produce compounded preparations. [2]

What This Means in Practice

The practical consequence: a patient ordering "compounded bremelanotide" from an online pharmacy is almost certainly receiving a product whose legal status is questionable. The FDA has not taken widespread public enforcement action against individual 503A pharmacies compounding bremelanotide the way it did with semaglutide during the GLP-1 shortage period, but the legal framework leaves compounders with little protection if inspected.

No compounded bremelanotide product carries FDA-cleared labeling, no compounded version has been tested in a randomized controlled trial, and no outsourcing facility is authorized to produce it at scale.

The RECONNECT Trials: Clinical Evidence Behind the Approval

The FDA approval rested primarily on two identically designed Phase 3 trials called RECONNECT. Published in Obstetrics and Gynecology (2019), the combined population included 1,247 premenopausal women with a diagnosis of acquired, generalized HSDD. [3]

Primary Endpoints and Results

Both trials used the same co-primary endpoints:

1. Change from baseline in the Female Sexual Function Index desire domain (FSFI-desire)
2. Change from baseline in the Female Sexual Distress Scale-Desire/Arousal/Orgasm item 13 (FSDS-DAO item 13), which measures distress specifically related to low sexual desire

In the combined analysis, bremelanotide produced a statistically significant improvement in both endpoints versus placebo. The FSFI-desire domain score increased by a mean of 0.35 points more than placebo (P<0.001), and FSDS-DAO item 13 showed a mean reduction of 0.32 points more than placebo (P<0.001). [3]

These effect sizes are modest by objective measurement. The FDA acknowledged that the clinical meaningfulness of a 0.35-point FSFI change is debatable, but the agency accepted the co-primary endpoint framework as clinically relevant given the lack of validated HSDD treatment options at the time of review.

What the RECONNECT Data Cannot Justify

The RECONNECT trials enrolled only premenopausal women with acquired, generalized HSDD. Extrapolating the trial data to:

• Postmenopausal women
• Men with low sexual desire
• Women with situational or relationship-specific low desire
• Women on SSRIs or SNRIs (partially excluded from the trials)

...is not supported by the published evidence base. Any compounded bremelanotide product marketed for these off-label populations lacks both regulatory approval and RCT-level efficacy data.

Vyleesi Label Safety Requirements

The prescribing information contains safety requirements that any prescriber or compounder must understand before dispensing any bremelanotide formulation.

Cardiovascular Blood Pressure Warning

Bremelanotide produces a transient, dose-dependent increase in blood pressure. In the RECONNECT trials, the mean maximum increase was approximately 6 mmHg systolic and 3 mmHg diastolic, typically peaking within 12 minutes of injection and resolving by 12 hours. In a subset of patients, systolic increases exceeded 20 mmHg. [3]

The FDA label carries a specific cardiovascular warning: Vyleesi is contraindicated in patients with known cardiovascular disease, including uncontrolled hypertension. Prescribers must measure blood pressure before initiating therapy and counsel patients to avoid dosing if resting blood pressure is elevated.

This contraindication has direct relevance to compounding: a 503A pharmacy filling a compounded bremelanotide prescription cannot verify whether the patient received the same cardiovascular screening that the label requires. The prescriber retains full liability for adverse cardiovascular events in that scenario.

Nausea Incidence and Management

Nausea was the most common adverse event in the RECONNECT trials, occurring in approximately 40% of bremelanotide-treated women compared with 1% of placebo-treated women. [3] Severe nausea requiring treatment occurred in roughly 13% of the active-treatment group. The label recommends antiemetic pretreatment for patients who experience moderate-to-severe nausea, specifically citing intramuscular ondansetron as an option.

The nausea profile matters from a compounding standpoint. Patients seeking compounded formulations sometimes request lower doses (e.g., 1.0 mg or 0.5 mg) in hopes of reducing nausea while preserving efficacy. No published dose-response data support that lower subcutaneous doses maintain clinically meaningful efficacy for HSDD. This is a gap in the current evidence base.

Hyperpigmentation Risk with Repeated Dosing

Bremelanotide activates MC1R, the melanocortin receptor that stimulates melanogenesis. Chronic or high-frequency dosing can produce focal hyperpigmentation, particularly on the face, gingiva, and breasts. In clinical trial populations using the drug per label (approximately 8 doses per month maximum), hyperpigmentation occurred in about 1% of patients. [1]

The risk increases with use frequency. This is the primary pharmacologic rationale behind the "max 8 doses per month" label restriction. Compounded formulations used without this restriction, as sometimes marketed by online pharmacies without adequate prescriber oversight, carry a higher theoretical hyperpigmentation risk.

Drug Interactions: Naltrexone

The Vyleesi label contains a clinically significant drug-drug interaction warning: bremelanotide may attenuate the effects of naltrexone. Patients receiving naltrexone for opioid use disorder or alcohol use disorder should not use bremelanotide concurrently. [1] This interaction is often missed in telehealth settings where different providers manage different conditions without shared records.

Regulatory Enforcement Field

How the FDA Has Approached Bremelanotide Compounding

The FDA has not issued a specific guidance document or public warning letter publicly targeting compounded bremelanotide at the scale it has targeted compounded GLP-1 agonists. This relative enforcement quiet should not be read as implicit approval. The statutory framework under 503A and 503B is not dependent on active enforcement to create legal risk; the prohibition on essentially-a-copy products exists independently of whether FDA has issued a warning letter.

The FDA's compounding compliance and enforcement page summarizes the agency's general framework. The key principle: FDA-approved drugs are not candidates for routine outsourcing-facility compounding unless they appear on the relevant bulks list or the commercial product is in shortage. Vyleesi has not been placed on the FDA drug shortage list. [2]

Shortage Status

The FDA's drug shortage database shows no active or resolved shortage for bremelanotide as of mid-2025. A shortage designation would open a narrow but meaningful legal window for 503B outsourcing facilities; that window does not currently exist. Prescribers citing "shortage" as justification for compounded bremelanotide prescriptions are doing so without a current factual basis.

State Pharmacy Board Considerations

Federal law sets the floor; state pharmacy boards set additional requirements. Several states impose stricter "essentially a copy" interpretations than FDA's guidance. California, New York, and Texas pharmacy boards have each issued clarifications specifying that commercially available drugs require documented clinical differentiation before a 503A compounding is permissible. Prescribers practicing in these states face added scrutiny.

Comparing Vyleesi to Compounded Alternatives: A Clinical Decision Framework

When a prescriber considers whether to write for brand Vyleesi versus a compounded preparation, the following decision points apply:

Is the Patient Premenopausal with Acquired, Generalized HSDD?

If yes, brand Vyleesi is the only FDA-approved option. Compounding is not indicated absent documented inability to use the commercial product (allergy to an excipient, documented cost barrier with commercial prior authorization exhausted, documented dose intolerance requiring a non-standard dose).

If no (postmenopausal, male, situational HSDD), neither the brand nor any compounded version has an approved indication. Prescribing is off-label regardless of source. That does not automatically make it inappropriate, but it does mean the prescriber must document the clinical rationale and obtain informed consent addressing the off-label nature of the treatment.

Has Commercial Prior Authorization Been Attempted?

Insurance coverage for Vyleesi is inconsistent. The brand list price is approximately $800 to $1,000 per month, which leads some patients and prescribers to seek compounded versions for cost reasons. Cost alone does not satisfy the "clinical differentiation" requirement under 503A. Prescribers should document prior authorization attempts and denial letters before pivoting to a compounding pharmacy.

Is the Compounding Pharmacy 503A or 503B?

A 503A pharmacy compounding bremelanotide for an individual named patient under a valid prescription exists in a gray zone but is not automatically illegal if clinical differentiation is documented. A 503B outsourcing facility producing bremelanotide in bulk without it being on the bulks list is operating outside the statutory framework entirely.

Post-Market Surveillance and Real-World Safety Data

The RECONNECT trial safety data covered approximately 24 weeks of observation. Post-market pharmacovigilance under the FDA's Sentinel system has not produced a publicly available signal report specific to bremelanotide as of mid-2025. The FDA Adverse Event Reporting System (FAERS) database contains bremelanotide adverse event submissions, dominated by nausea, flushing, and headache, consistent with the trial data.

One area under ongoing observation is the interaction between bremelanotide's MC1R activity and existing nevi or melanocytic lesions. Dermatology case reports have described accelerated pigmentation of pre-existing moles in patients using bremelanotide more frequently than the label recommends. Patients with a personal or family history of melanoma should be counseled specifically about this theoretical concern before initiating treatment, even with the brand product.

The Endocrine Society's clinical practice guidance on female sexual dysfunction, last updated in 2019, notes that "data on long-term safety of bremelanotide beyond 24 weeks are limited," a statement that remains accurate given the absence of published long-term extension data. [4]

Prescriber Responsibilities and Documentation Standards

A prescriber signing off on any bremelanotide prescription, whether for brand Vyleesi or a compounded preparation, should document:

1. HSDD diagnosis established using a validated instrument (FSFI, DSDS, or HSDD Screener for Women)
2. Exclusion of underlying medical, psychiatric, or relational contributors
3. Premenopausal status confirmed
4. Cardiovascular screening completed, including resting blood pressure measurement
5. Naltrexone use reviewed and ruled out
6. Patient counseled on nausea, hyperpigmentation, and the 8-dose-per-month limit
7. For compounded preparations: documented clinical rationale for why the commercial product is not suitable

The American College of Obstetricians and Gynecologists (ACOG) has not issued a standalone practice bulletin on bremelanotide, but its guidance on sexual dysfunction in women references the FDA-approved pharmacologic options as second-line after non-pharmacologic approaches. [5]

FAQ